See other companies on Welcome to the Jungle
Embleema
Health data platform for research
- 1-20 employees
- Healthcare
- B2C
- B2B
- Biology
- SaaS
- Data Analysis
- Metuchen, NJ
Jump to section
Company mission
To accelerate new drug discovery and release new treatments sooner.
Our take
Clinical research continues to grow at a rapid pace, with scientists in this industry producing steadily increasing amounts of research. Embleema wants to support this with its Data-as-a-Service platform that can speed up the whole process from initial discovery and candidate enrolment, to collecting data, to managing regulations - bringing precision medicine to patients faster.
The first platform of its kind, Embleema unifies clinical, real-world, molecular data, analytics and regulatory submissions, streamlining the review process for new drugs. It is not only able to support faster review processes, but also save users time and money that can be better spent on advancing their work.
Embleema is already used by the FDA for its regulatory evaluation of health products involving genomic datasets, as well as being utilised in over half of the top 10 Investigational sites in the US. This is a clear stamp of approval from the industry, and bodes well for the future of the company moving forwards.
Kirsty
Company Specialist at Welcome to the Jungle
Funding (1 round)
Feb 2019
$3.5m
SERIES A
Total funding: $3.5m
This company has top investors
Leadership
Robert Chu
(CEO)Former SVP of Technology Solutions at IQVIA. Previously spent 7.5 years at IMS Health, ultimately as President of Asia Pacific and China; and 8.5 years at IBM, ultimately as Director of the Telecom, Media and Utilities Sector in France.
Nicolas Schmidt
(CPO)Co-Chair of the Mobile Health Applications Working Group at the Consumer Technology Association. Was Head of Healthcare Products at Nokia, Lead Product Manager at Withings.